Madrigal Pharmaceuticals, Inc. Stock News

Madrigal Pharmaceuticals just commercialized its first medicine. Viking Therapeutics has a mid-stage candidate with great potential.

Madrigal Pharmaceuticals scored a historical regulatory approval last month. Even so, the market has been taking a cautious approach to Madrigal's shares.

Right now, biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. All of this is thanks to new innovation, millions of ret

Viking's drug candidate has shown promise in clinical studies as a potential weight loss medicine. Madrigal just launched the first (and so far only) medicine approved by the U.S. for NASH.

The Food and Drug Administration recently granted accelerated approval for Rezdiffra, a potential blockbuster for Madrigal Pharmaceuticals. At its peak, the drug could bring in more than $5 billion in

After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market i

Madrigal earned the first approval for a medicine in an area with a high unmet need. The commercial opportunity for this therapy, which treats a liver disease, looks exciting.

Last week's FDA approval of Rezdiffra in treating NASH is a huge milestone for Madrigal. Lilly and Novo Nordisk look much more impressive than Madrigal in most ways.

Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.

On March 14, Madrigal Pharmaceuticals, Inc. announced that the FDA has granted accelerated approval for Rezdiffra, for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fi

Madrigal just won a milestone approval for Rezdiffra in treating NASH. NASH presents a massive potential market that could be worth tens of billions of dollars annually.

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) stock is taking off today, after the U.S. Food & Drug Administration (FDA) approved the biotech company's drug for the treatment of non-alcoholic steatohepa

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) shares soared after the biopharmaceutical firm revealed its live disease drug Rezdiffra has won US Food and Drug Administration (FDA) approval.   Shares of

Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.

Madrigal Pharmaceuticals (NASDAQ: MDGL ) stock is rising higher on Friday after the company got positive news from the Food and Drug Administration (FDA)! The big news here is the FDA granting acceler